LONDON – Actelion Pharmaceuticals Ltd. is paying €10 million (US$12.9 million) in cash for the option to acquire Trophos SA for up to €195 million cash once it gets Phase III data on olesoxime, a treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. (BioWorld International) Read More
